• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 8:08:08 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email
    8-K
    0000899460false00008994602025-05-082025-05-08

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 08, 2025

     

     

    MannKind Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    000-50865

    13-3607736

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1 Casper Street

     

    Danbury, Connecticut

     

    06810

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (818) 661-5000

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.01 per share

     

    MNKD

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02. Results of Operations and Financial Condition.

    On May 8, 2025, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibit 99.1

    Press release dated May 8, 2025

     

     

    Exhibit 104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    MannKind Corporation

     

    Date: May 8, 2025

    By:

    /s/ David Thomson, Ph.D., J.D.

    David Thomson, Ph.D., J.D.

    Corporate Vice President, General Counsel and Secretary

     

     


    Get the next $MNKD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNKD

    DatePrice TargetRatingAnalyst
    4/10/2025$12.00Outperform
    Mizuho
    2/10/2025$11.00Outperform
    Wedbush
    12/20/2024$9.00Overweight
    Wells Fargo
    12/19/2024$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    9/9/2024$7.00 → $8.00Outperform
    Leerink Partners
    6/13/2024$8.00Buy
    Rodman & Renshaw
    10/10/2023$10.00Outperform
    Wedbush
    2/28/2022$6.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MNKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Castagna Michael disposed of 39,500 shares, decreasing direct ownership by 2% to 2,255,336 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      4/4/25 8:54:43 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP Operations Sabella Lauren M covered exercise/tax liability with 16,407 shares, decreasing direct ownership by 4% to 357,849 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      3/28/25 8:20:54 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Chief Financial Officer Prentiss Christopher B was granted 103,600 shares (SEC Form 4)

      4/A - MANNKIND CORP (0000899460) (Issuer)

      3/28/25 8:20:41 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Financials

    Live finance-specific insights

    See more
    • MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

      Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024Advanced pipeline: Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysisMNKD-201: Expect to continue to next phase of global development in 2H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter 2025 and provided a business update. "The first quarter was marked by strong y

      5/8/25 8:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 2

      5/1/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th

      2/26/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    SEC Filings

    See more
    • SEC Form 10-Q filed by MannKind Corporation

      10-Q - MANNKIND CORP (0000899460) (Filer)

      5/8/25 8:10:25 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNKIND CORP (0000899460) (Filer)

      5/8/25 8:08:08 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by MannKind Corporation

      DEFA14A - MANNKIND CORP (0000899460) (Filer)

      4/1/25 5:02:02 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

      Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024Advanced pipeline: Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysisMNKD-201: Expect to continue to next phase of global development in 2H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter 2025 and provided a business update. "The first quarter was marked by strong y

      5/8/25 8:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 2

      5/1/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

      Daly to showcase striking "Tired of Pricks?" livery for JHR at Acura Long Beach Grand Prix, Sunday, April 13Indiana native is the only known U.S. pro racing driver competing full-time with T1D WESTLAKE VILLAGE, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, announced today a continued partnership with Juncos Hollinger Racing (JHR) driver Conor Daly for the 2025 NTT INDYCAR Series season. Daly, who was diagnosed with diabetes at age 14, is the only known U.S. pro racing driver competing full-t

      4/7/25 12:30:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Mannkind with a new price target

      Mizuho initiated coverage of Mannkind with a rating of Outperform and set a new price target of $12.00

      4/10/25 12:42:30 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Mannkind with a new price target

      Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00

      2/10/25 7:01:41 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Mannkind with a new price target

      Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $9.00

      12/20/24 7:44:06 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Leadership Updates

    Live Leadership Updates

    See more
    • MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

      MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

      1/5/22 6:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

      SC 13G/A - MANNKIND CORP (0000899460) (Subject)

      2/13/24 5:08:11 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

      SC 13G/A - MANNKIND CORP (0000899460) (Subject)

      1/22/24 12:56:57 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

      SC 13G/A - MANNKIND CORP (0000899460) (Subject)

      2/9/23 11:25:13 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care